Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DUT | P33316 | 10/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11472497 | 0.83 | PKM (0.55) | PKMALDH1A1LMNADUTL3MBTL1 | |
| SCHEMBL7140825 | 0.83 | PKM (0.55) | PKMALDH1A1LMNADUTL3MBTL1 | |
| SCHEMBL23873265 | 0.81 | PKM (0.60) | PKMALDH1A1LMNADUTL3MBTL1 | |
| SCHEMBL19171430 | 0.77 | PKM (0.52) | PKMALDH1A1LMNADUTL3MBTL1 | |
| SCHEMBL25739570 | 0.77 | PKM (0.49) | PKMALDH1A1LMNADUTL3MBTL1 | |
| SCHEMBL26231009 | 0.76 | PKM (0.59) | PKMALDH1A1LMNADUTCRBN | |
| SCHEMBL27219170 | 0.75 | PKM (0.54) | PKMALDH1A1LMNADUTL3MBTL1 | |
| SCHEMBL26040211 | 0.75 | PKM (0.62) | PKMALDH1A1LMNADUTL3MBTL1 | |
| SCHEMBL27219168 | 0.75 | PKM (0.54) | PKMALDH1A1LMNADUTL3MBTL1 | |
| SCHEMBL27219275 | 0.75 | PKM (0.54) | PKMALDH1A1LMNADUTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249548-A1 | Nucleoside Analog or Salts of the Same | GIFU UNIVERSITY (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1798225-A1 | NUCLEOSIDE ANALOGUES OR SALTS THEREOF | Gifu University (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249548-A1 | Nucleoside Analog or Salts of the Same | NSUN2, RNMT, RNGTT | PKM 793/4885ALDH1A1 1694/4885LMNA 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.